statistiche ricercatore

Continente	#
NA - Nord America	772
AS - Asia	633
EU - Europa	627
SA - Sud America	54
AF - Africa	15
Continente sconosciuto - Info sul continente non disponibili	2
Totale	2.103

Nazione	#
US - Stati Uniti d'America	733
GB - Regno Unito	278
CN - Cina	196
SG - Singapore	196
IT - Italia	110
VN - Vietnam	68
RU - Federazione Russa	50
BR - Brasile	44
DE - Germania	42
NL - Olanda	39
BD - Bangladesh	37
SE - Svezia	36
CA - Canada	30
HK - Hong Kong	30
IN - India	27
TR - Turchia	23
FR - Francia	22
FI - Finlandia	16
KR - Corea	16
IE - Irlanda	11
CI - Costa d'Avorio	10
BE - Belgio	9
JP - Giappone	8
SA - Arabia Saudita	4
UZ - Uzbekistan	4
AE - Emirati Arabi Uniti	3
AR - Argentina	3
ID - Indonesia	3
MX - Messico	3
UA - Ucraina	3
CO - Colombia	2
DK - Danimarca	2
GT - Guatemala	2
JM - Giamaica	2
MD - Moldavia	2
PH - Filippine	2
PK - Pakistan	2
PL - Polonia	2
TH - Thailandia	2
ZA - Sudafrica	2
A2 - ???statistics.table.value.countryCode.A2???	1
AM - Armenia	1
AO - Angola	1
AT - Austria	1
AZ - Azerbaigian	1
CH - Svizzera	1
CL - Cile	1
DO - Repubblica Dominicana	1
EC - Ecuador	1
EE - Estonia	1
EU - Europa	1
IQ - Iraq	1
JO - Giordania	1
KG - Kirghizistan	1
LB - Libano	1
MY - Malesia	1
NG - Nigeria	1
NP - Nepal	1
OM - Oman	1
PA - Panama	1
PS - Palestinian Territory	1
PT - Portogallo	1
PY - Paraguay	1
QA - Qatar	1
RO - Romania	1
SY - Repubblica araba siriana	1
TN - Tunisia	1
UY - Uruguay	1
VE - Venezuela	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	2.104

Nome	#
Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies : evidence from Phase I studies in healthy volunteers	281
Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients : an observational study in real-life settings	231
Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers : a randomized, open-label, 2-period, single-dose, crossover phase 1 study	224
Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients	203
Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients	201
Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with Gram-positive infections	191
Comparison of the ARK Immunoassay With High-Performance Liquid Chromatography With Ultraviolet Detection for Therapeutic Drug Monitoring of Linezolid	185
Limited Sampling Strategies for the Estimation of Raltegravir Daily Exposure in HIV-Infected Patients	181
Is it time to revise antiretrovirals dosing? : a pharmacokinetic viewpoint	173
Comparison of the QMS® analyzer with HPLC-UV for the quantification of lamotrigine concentrations in human plasma samples	164
Lights and shadows of the actual European guidelines on bioanalytical method validation : the case of raltegravir	161
Totale	2.195

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	25	0	0	0	0	0	0	0	0	0	0	21	4
2021/2022	122	11	1	0	2	13	4	9	5	30	13	7	27
2022/2023	195	28	35	18	22	14	36	0	8	27	4	3	0
2023/2024	99	0	10	10	8	30	13	0	5	0	1	10	12
2024/2025	315	6	17	3	39	28	16	5	25	29	46	25	76
2025/2026	708	73	60	102	60	80	47	102	18	48	47	71	0
Totale													2.195

IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca